The NEJM publishes phase 3 PEGASUS study results comparing pegcetacoplan to eculizumab for PNH
· Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in haemoglobin levels and showed improvements in key clinical outcomes · Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the EMA STOCKHOLM, Sweden and WALTHAM, Mass, USA - Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The New England Journal of Medicine (